首頁 › 卵巢癌 › 明尼蘇達 › Minneapolis
Minneapolis, MN 的 卵巢癌 臨床試驗
24 項針對 卵巢癌 的研究正在 Minneapolis（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- Minneapolis VA Medical Center, Minneapolis
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
招募中3 期
- Masonic Cancer Center, University of Minnesota, Minneapolis
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- Abbott-Northwestern Hospital, Minneapolis
- Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 距離 5 英里
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- Health Partners Frauenshuh Cancer Center, Saint Louis Park · 距離 5 英里
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
招募中2 期
- University Of Minnesota /ID# 277850, Minneapolis
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
招募中2 期
- University of Minnesota - Minneapolis /ID# 275718, Minneapolis
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780, Saint Louis Park · 距離 5 英里
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
招募中2 期
- Minnesota Oncology-Minneapolis, Minneapolis
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
招募中1 期
- University of Minnesota Masonic Cancer Center, Minneapolis
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
招募中1 期
- University of Minnesota, Minneapolis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- University of Minnesota/Masonic Cancer Center, Minneapolis
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Minneapolis
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
招募中
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- 還有 2 項
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
招募中3 期
- Abbott-Northwestern Hospital, Minneapolis
- Hennepin County Medical Center, Minneapolis
- Health Partners Inc, Minneapolis
- 還有 2 項
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
招募中1/2 期
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
招募中2 期
- 518, Minneapolis
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
招募中2 期
- University of Minnesota - Masonic Cancer Center, Minneapolis
UNTOLD Ovarian Cancer Unmet Needs Survey
招募中觀察性研究
- Masonic Cancer Center, Minneapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
招募中3 期
- Minnesota Oncology Hematology PA, Minneapolis
Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
招募中歡迎健康志工
- University of Minnesota, Minneapolis
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
招募中1 期
- University of Minnesota, Minneapolis
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
招募中觀察性研究歡迎健康志工
- Allina Health Cancer Institute, Minneapolis
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
招募中2 期
- SCRI - Minnesota Oncology Hematology, P.A., Minneapolis
- University of Minnesota, Minneapolis
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
招募中1 期
- University of Minnesota, Minneapolis
其他城市的 卵巢癌 試驗
- Houston, TX89 項研究
- New York City, NY69 項研究
- Boston, MA61 項研究
- Los Angeles, CA50 項研究
- Nashville, TN49 項研究
- Arlington, VA46 項研究
- Philadelphia, PA44 項研究
- Columbus, OH39 項研究
- St. Louis, MO38 項研究
- Chicago, IL36 項研究
- San Antonio, TX31 項研究
- Cleveland, OH30 項研究
Minneapolis 的其他研究
- 非小細胞肺癌27 項研究
- 乳癌27 項研究
- 前列腺癌23 項研究
- 癌症（所有類型）22 項研究
- 心臟衰竭21 項研究
- 急性髓系白血病20 項研究
- 肺癌20 項研究
- 大腸直腸癌19 項研究
- 子宮內膜癌18 項研究
- 帕金森氏症17 項研究
- 心血管疾病15 項研究
- 冠狀動脈疾病13 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。